How it works
Cagrilintide is a 37-residue acylated amylin analog engineered for extended pharmacokinetics. It engages amylin and calcitonin receptors, producing effects on satiety, gastric emptying, and glucagon secretion that are mechanistically distinct from incretin pathways. In recent metabolic research it is most often studied alongside GLP-1 agonists, where the dual mechanism produces additive effects on body composition and glycemic markers in animal models.
Learn more about the science →Certificate of Analysis+
LC-MS identity, HPLC purity (≥99%), mass spec confirmation, endotoxin assay, third-party ISO-17025 verification.
View full certificate →Specifications+
Storage & handling+
Lyophilized: −20°C, 24 months. Reconstituted: 2–8°C, 30 days. Bacteriostatic water; protect from light.
We ship in insulated parcels with phase-change cooling and a tamper-evident seal.
FAQs+
Why is cagrilintide typically studied alongside semaglutide?+
Different receptor systems (amylin/calcitonin vs. GLP-1). The combination produces additive effects on body weight and glycemic markers in published animal work.
What's the half-life relative to native amylin?+
Native amylin: ~13 minutes. Cagrilintide's acylation extends this to ~7 days, enabling once-weekly dosing in research protocols.
Is cagrilintide stable in solution at room temperature?+
Briefly. Store reconstituted at 2–8°C and minimize ambient exposure.
Does cagrilintide require the same reconstitution as semaglutide?+
Yes. Bacteriostatic water, gentle swirl, 2–8°C.
What lot documentation is provided?+
Every vial: batch-specific COA with full identity, purity, mass spec, endotoxin, plus third-party verification.
Is cagrilintide subscription-eligible?+
Yes. 15% off on a 60-day cycle.
The research behind this compound, cited in full.
Provided for context only. None of the studies cited below evaluate hábit material specifically; they document the published literature on the compound and its mechanism. Research-use claims are not therapeutic claims.
- [01] Lau DC. et al. Lancet 398 (2021): 2160–2172.
- [02] Enebo LB. et al. Lancet 397 (2021): 1736–1748.
- [03] Kruse T. et al. J Med Chem 64 (2021): 11183–11194.
- [04] Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Verified buyer notes
Initials only — every quote is verified against an order record. We don’t ghost-write reviews.
“COA matched what we ran in-house. Powder reconstituted clean, no haze. Did exactly what we needed it to.”
“Switched after two bad lots from a previous source. Three orders in, zero issues.”
“Asked support a purity question and got the raw HPLC trace back within the hour. That transparency is why we reorder.”